Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Cannabis compounds tested for MS brain fog and bladder troubles

NCT ID NCT06261489

Symptom relief Sponsor: University of Calgary Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Sep 16, 2026 · Updated 4 times

Summary

This study looks at how two parts of cannabis, THC and CBD, affect thinking and bladder symptoms in people with Multiple Sclerosis (MS). Thirty adults with MS will take either THC or CBD oil for 15 weeks and complete tests and questionnaires. The goal is to see if one compound helps more with mental processing speed and bladder control.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 2

Tests whether the treatment actually works, and watches for side effects, in a larger group.

Participants

About 30 people

The number the study aims to enrol. It can still change while the study runs.

Started

Dec 2025

Expected to finish

Sep 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

26 to 59 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Age between 26 and 59 years inclusive. * Confirmed diagnosis of Multiple Sclerosis as per McDonald criteria (any type) \[12\] * Symptoms of neurogenic lower urinary tract dysfunction (NLUTD) as measured by neurogenic bladder symptom score (NBSS), with a minimum score of 7. * If already on a medication for NLUTD, must be stable on this medication for at least 4 weeks. * Sexually active men and women of child-bearing potential must agree to use adequate contraception. * Written informed consent. Exclusion Criteria: * Major psychiatric disorder such as schizophrenia or bipolar disorder * Major neurological disorder which could affect cognition such as dementia, traumatic brain injury. * Seizure disorder * Use of antipsychotic medication * Use of benzodiazepines other than exclusively at night/bedtime * Experienced a MS relapse in the last ninety (90) days. * Current use of cannabis or CBM greater than 3x/week. * Currently using cannabis/CBM less than 3x/week and being unwilling to abstain for the duration of the study. * Visual acuity (binocular) worse than 20/70 (in order to complete the cognitive outcomes) * Significant upper extremity disability that would interfere with the cognitive tests battery. * Indwelling catheter use/urinary diversion * Pregnant or Breastfeeding

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Multiple sclerosis are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

cannabis dependence multiple sclerosis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Multiple sclerosis

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    2 sites. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • University of Calgary

    RECRUITING

    Calgary, Alberta, Canada

  • University of Calgary Foothills Medical Center

    RECRUITING

    Calgary, Alberta, Canada

More trials for these conditions

Other studies related to the condition(s) this trial covers.